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Transplantation-associated thrombotic microangiopathy (TA-TMA) is a devastating complication of hema-
topoietic stem cell transplantation. TA-TMA likely represents the ﬁnal stage of vascular endothelial injury;
however, its pathophysiology is largely unknown, making clinical management difﬁcult. Recently, the asso-
ciation of neutrophil extracellular traps (NETs) with the development of thrombotic thrombocytopenic
purpura and hemolytic uremic syndrome has been reported. Thus, we explored whether NETs are also
relevant to the occurrence of TA-TMA. We retrospectively analyzed post-transplant trends of serum NET
levels in 90 patients, 11 of whom developed TA-TMA. Relative to baseline (before the conditioning regimen),
elevated serum NET levels either at 4 weeks after transplantation or as early as the day of transplantation
were associated with signiﬁcantly increased risk of TA-TMA. In contrast, thrombomodulin, a potential marker
for TA-TMA, was not helpful to predict the occurrence of TA-TMA in our study. In addition, we directly
detected glomerular deposition of NETs in 2 TA-TMA patients. Increased NET levels are a signiﬁcant risk factor
for TA-TMA, suggesting that NET level is a useful biomarker for TA-TMA.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION the kidney and other organs after allo-SCT [1], being distinct
Thrombotic microangiopathies (TMAs) are microvascular
occlusive disorders characterized by thrombocytopenia,
systemic or intrarenal aggregation of platelets, mechanical
injury to erythrocytes, and ischemic organ damage [1]. The
most common TMAs are thrombotic thrombocytopenic
purpura (TTP), due to decreased activity of a disintegrin and
metalloproteasewith a thrombospondin type 1motif domain
13 (or ADAMTS13) [2], or hemolytic uremic syndrome (HUS)
[3], due to infection with Shiga toxineproducing Escherichia
coli in diarrhea-positive HUS. However, TMAs are also asso-
ciated with other clinical conditions, including allogeneic
stem cell transplantation (allo-SCT), tumor, chemotherapy,
pregnancy, and autoimmune disease. Although allo-SCT is
highly effective for eradicating hematological malignancies,
it has a higher risk of treatment-related mortality.
One devastating complication of allo-SCT is
transplantation-associated TMA (TA-TMA), affecting 10% to
25% of patients [4], 60% to 75% of whom may die within 3
months [1,5]. TA-TMA is associated with a variety of risk
factors, such as acute graft-versus-host disease (GVHD),
infections, unrelated or HLA-mismatched donor grafts,
female sex, and the use of a calcineurin inhibitor or sirolimus
[1,4]. Thus, TA-TMA is a syndrome representing a “ﬁnal
common pathway” of vascular endothelial injury damagingedgments on page 1689.
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13.09.005from TTP and HUS. The effective management of TA-TMA is
currently hindered by the lack of early diagnostic biomarkers
for TA-TMA, and the discovery of early markers is an
important step for the successful treatment of TA-TMA.
Neutrophil extracellular traps (NETs), originally described
as a component of innate antimicrobial immunity, are
extracellular ﬁbrillar matrices composed of chromatin and
granule proteins released by activated neutrophils [6]. NETs
are known to contribute to autoimmunity and thrombosis;
systemic lupus erythematosus [7,8], small-vessel vasculitis
[9], pre-eclampsia [10], sepsis [11,12], transfusion-related
acute lung injury [13,14], deep vein thrombosis [15], and
atherosclerosis [16]. NETs in the peripheral circulation are
associated with the development of several types of TMA,
such as TTP and HUS [17]. The authors in the study specu-
lated that NETs may provide a second hit that precipitates
acute disease in patients at high risk for TMA [17]. To date,
however, the involvement of NETs in the pathogenesis of TA-
TMA remains to be elucidated. Here, we analyzed the serum
NET proﬁles after allo-SCT to determine the effects of NETs
on TA-TMA and to evaluate the use of NET levels as
a predictive marker for TA-TMA.METHODS
Patient Characteristics and Allo-SCT Procedures
We retrospectively reviewed the clinical history of patients who
underwent allo-SCT in our department between September 2007 and April
2012 and survived at least 28 days after allo-SCT. Ninety patients were
included in the study. Patient characteristics and allo-SCT procedures are
summarized in Table 1.
Underlying diagnoses included acute myelogenous leukemia, myelo-
dysplastic syndrome, acute lymphoblastic leukemia, malignant lymphoma,Transplantation.
Table 1
Characteristics of All SCT Patients
Variables All SCT Patients
(N ¼ 90)
TMA Patients
(N ¼ 11)
Sex, male/female 50/40 8/3
Age, y, median (range) 48.5 (17-66) 44 (21-60)
Over/under 50 40/50 5/6
Disease, AML/MDS/ALL/ML/ATL/
MM/AA
34/10/16/21/7/1/1 6/1/1/3/0/0/0
SCT risk, high/standard 48/42 9/2
Disease status, progressive/
controlled
36/54 8/4
Prior allo-SCT, yes/no 10/80 2/9
Donor source, R-BM/R-PB/
UR-BM/CBT
17/3/43/27 1/0/6/4
ABO mismatch, major þ minor/
major/minor/none
13/18/19/40 0/3/1/7
Conditioning, MAC/RIC 39/51 7/4
GVHD prophylaxis
CyA/FK506 based 16/74 1/10
Methotrexate/mycophenolate
mofetil/both
47/7/18 4/1/4
Follow-up, day, median (range) 700 (98-1660) 778 (140-1051)
AML indicates acute myelogenous leukemia; MDS, myelodysplastic
syndrome; ALL, acute lymphoblastic leukemia; ML, malignant lymphoma;
ATL, adult T cell leukemia; MM, multiple myeloma; AA, aplastic anemia;
R-BM, related bone marrow; R-PB, related peripheral blood stem cell;
UR-BM, unrelated bone marrow; CBT, cord blood transplantation; MAC,
myeloablative conditioning; RIC, reduced-intensity conditioning; CyA,
cyclosporine A.
Y. Arai et al. / Biol Blood Marrow Transplant 19 (2013) 1683e16891684adult T cell leukemia, multiple myeloma, and aplastic anemia. Patients were
divided into high-risk and standard-risk groups, according to the trans-
plantation risk. Standard-risk criteria were as follows: (1) acute leukemia in
ﬁrst complete remission phase, or (2) de novo refractory anemia and ringed
sideroblasts, or (3) malignant lymphoma/multiple myeloma in complete or
partial remission phase, or (4) all nonmalignant hematological diseases. All
other patients were considered high risk.
Disease status at SCT was divided into controlled and progressive
disease. Controlled disease was deﬁned according to the relevant criteria:
(1) partial or complete remission (acute myelogenous leukemia, acute
lymphoblastic leukemia, malignant lymphoma, adult T cell leukemia, and
multiple myeloma), (2)<10%marrow blasts (myelodysplastic syndrome), or
(3) all nonmalignant hematological diseases. As for conditioning regimens,
deﬁnitions of myeloablative conditioning and reduced-intensity condi-
tioning were consistent with those of the reduced-intensity conditioning
regimen workshop [18].
TA-TMA Diagnosis and Therapy
TA-TMA was diagnosed according to Blood and Marrow Transplant
Clinical Trials Network Toxicity Committee criteria [5]: (1) erythrocyte
fragmentation and 2 schistocytes per high-power ﬁeld of a peripheral
smear, (2) concurrent increased serum lactate dehydrogenase levels above
institutional baseline, (3) concurrent renal dysfunction (doubling of serum
creatinine levels from baseline or 50% decrease in creatinine clearance from
baseline) and/or neurological dysfunction without other explanations, and
(4) negative direct and indirect Coombs test results. TA-TMA severity was
assessed as follows: grade 1, schistocytes without clinical consequences;
grade 2, presence of schistocytes and elevated creatinine levels 3-fold the
upper limit of normal; grade 3, presence of schistocytes and elevated
creatinine levels >3-fold the upper limit of normal but not requiring dial-
ysis; and grade 4, presence of schistocytes with renal failure either requiring
dialysis and/or associated with encephalopathy. Patients who were grades 2
to 4 at least once were diagnosed with TA-TMA and included in the TMA
group. Therapeutic strategies for TA-TMA, such as reduction of calcineurin
inhibitor, infusion of fresh frozen plasma, administration of recombinant
thrombomodulin, or plasma exchange, were determined by the attending
physicians.
Serum NET Level Evaluation
Serum samples were collected at 3 different times (before conditioning
regimen [PRE], day of transplantation [Day0], and in the 4th week [4WK])
and preserved at 80C. As control samples, sera from healthy volunteers
were obtained (N ¼ 11; 9 men and 2 women; median age 25.5 years [range,
24 to 44]). Protocols were approved by the Ethics Committee of Kyoto
University, and written informed consent was obtained from each patient.Serum NETs were quantiﬁed using Quant-iT PicoGreen double-stranded
DNA (dsDNA) Reagent (#P7581, Molecular Probes, Eugene, OR) according
to the manufacturer’s instructions (PicoGreen assay). Fluorescence was
recorded in a ﬂuorometer (Fluoroskan Ascent, #5210470, Thermo Fisher
Scientiﬁc K.K., Yokohama, Japan) with ﬁlter settings of 485 nm (excitation)
and 538 nm (emission). Capture ELISA was used to measure the dsDNA
combined with myeloperoxidase (MPO) granules (MPO-DNA ELISA) [13].
Values are expressed as absorbance above control and compared with
values obtained using the PicoGreen assay.
Serum Thrombomodulin Level Evaluation
Serum thrombomodulin levels were determined using ELISA for
thrombomodulin (#DTHBD0, R&D Systems, Minneapolis, MN) according to
the manufacturer’s instructions.
Immunoﬂuorescence Staining of Kidneys Obtained from TA-TMA
Patients
Parafﬁn-embedded kidney samples from 2 TA-TMA patients were
prepared, mounted on glass slides, deparafﬁnized in xylene (#244-00081,
Wako Pure Chemical Industries, Tokyo, Japan), and rehydrated through
a graded alcohol series and distilledwater. After antigen retrievalwith citrate
buffer (#S1700, Dako, Tokyo, Japan), specimens were blocked for 1 hour in
10% FCS in PBS (#16030-074,Molecular Probes). Primaryantibody incubation
was overnight at 4C with 10 mg/mL rabbit monoclonal anti-human MPO
antibody (#ab45977, Abcam, Tokyo, Japan), followed by 1 hour of incubation
with anti-rabbit IgG-Alexa Fluor 488 (2 mg/mL, #A-11008, Molecular Probes).
Nuclear and extracellular dsDNA were detected by staining with 500 nM
Sytox Orange Nucleic Acid Stain (#S11368, Molecular Probes). Slides were
coverslipped with mounting media (ProLong Gold Antifade Reagent,
#P36930, Molecular Probes) and analyzed by confocal laser scanning ﬂuo-
rescence microscopy (Digital Eclipse C1; Nikon, Tokyo, Japan).
Statistical Analysis
Overall survival after allo-SCT was calculated with Kaplan-Meier
methods and compared by log-rank tests. Nonrelapse mortality was
analyzed using Gray’s methods, considering relapse as a competing risk.
Serum NET and thrombomodulin levels were compared by unpaired t-tests
and repeated-measures analysis of variance with Dunnett’s multiple
comparisons test. Univariate analysis of the cumulative incidence of TA-TMA
was performed using Gray’s methods, considering early death as
a competing risk; factors with signiﬁcance or borderline signiﬁcance (P < .1)
were subjected to a multivariate analysis using Fine-Gray proportional
hazards models. Cumulative incidence of acute GVHD (grades II to IV) and
early bacterial infection (documented bacteremia up to Day 100) was
calculated using Gray’s method, considering relapse or early death as
a competing risk. Statistical analyses were performed using R (version
2.13.0; R Foundation for Statistical Computing, Vienna, Austria) and
GraphPad Prism (version 6.00; GraphPad Software, La Jolla, CA). The alpha
level of all tests or the P value was set at .05.
RESULTS
Incidence and Clinical Outcomes of TA-TMA
Within the median follow-up of 700 days (range, 98 to
1660 days), TA-TMAwas diagnosed in 11 cases, at amedian of
42 days (range, 19 to 78 days) after allo-SCT, and the cumu-
lative incidence at Day 100 was 12.2% (95% conﬁdence
interval, 6.5% to 19.9%) (Table 2). Therapeutic interventions
for TA-TMA (fresh frozen plasma infusion in 5 patients,
plasma exchange in 3, and recombinant thrombomodulin
administration in 1) had limited effects, resulting in the
deterioration and subsequent death in 5 patients. The 1-year
overall survival was signiﬁcantly lower (31.2% versus 69.8% [P
< .01]) and nonrelapse mortality signiﬁcantly higher (39.0%
versus 9.3% [P ¼ .03]) in, respectively, the TMA group than in
the non-TMA group (Figure 1A,B).
PicoGreen Assay Is Feasible for Evaluating Serum NETs
Estimations of NET levels obtained by MPO-DNA ELISA or
the cell-free dsDNA PicoGreen assay were positively corre-
lated in the analysis of 40 randomly selected specimens
(Pearson’s correlation coefﬁcient, R2 ¼ .57, P < .01, data not
shown), suggesting that NETs were the major source of the
serum dsDNA detected by the PicoGreen assay in accord with
Table 2
Characteristics of Patients with TA-TMA
Age
Sex
Disease
Status
Donor
Source
Conditioning GVHD
Prophylaxis
Acute
GVHD
TA-TMA Encephalopathy TA-TMA
Therapy
TA-TMA
Remission
Relapse Outcome
(Post-SCT Day)
1 59F MDS relapse CBT RIC Flu/Mel/TBI FK III
Day 43
Gr2
Day 42
22 d N Alive 1051
2 31F AML relapse R-BM RIC Flu/Mel FK/MTX/MMF I
Day 59
Gr2
Day 40
49 d Y
Day 482
Death (relapse) 798
3 44M ALL
CR1
CBT MAC CY/TBI FK/MMF II
Day 33
Gr3
Day 61
FFP/rTM 40 d N Alive 140
4 53M AML
PD
UR-BM MAC BU/CY FK/MTX Gr3
Day 20
67 d Y
Day 147
Alive 778
5 38F ML relapse CBT MAC Flu/Mel/TBI CyA/MTX Gr3
Day 46
FFP N N Death (MOF) 52
6 54M AML
PD
CBT MAC CY/TBI FK Gr4
Day 28
Y FFP/PE 99 d Y
Day 117
Death (relapse) 143
7 60M AML
CR1
UR-BM RIC Flu/Mel FK/MTX/MMF II
Day 13
Gr4
Day 19
Y PE 19 d Y
Day 124
Death (relapse) 263
8 60M ML
NC
UR-BM RIC Flu/Mel FK/MTX/MMF IV
Day 32
Gr4
Day 55
Y FFP N Y
Day 33
Death (relapse) 89
9 39M AML relapse UR-BM MAC CY/TBI FK/MTX IV
Day 23
Gr4
Day 56
Y FFP N N Death (TA-TMA) 101
10 36M ML relapse UR-BM MAC CY/TBI FK/MTX IV
Day 54
Gr4
Day 78
HD N N Death (infection) 143
11 21M AML
CR3
UR-BM MAC BU/CY FK/MTX/MMF III
Day 24
Gr4
Day 31
Y PE/HD N N Death (TA-TMA) 46
CR indicates complete remission; AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome; PD, progressive disease; NC, no change; Flu, ﬂudarabine;
Mel, melphalan; TBI, total body irradiation; CY, cyclophosphamide; BU, busulfan; MTX, methotrexate; MMF, mycophenolate mofetil; FFP, fresh frozen plasma;
ML, malignant lymphoma; rTM, recombinant thrombomodulin; PE, plasma exchange; Gr, grade; HD, hemodialysis; MOF, multiple organ failure; R-BM, related
bonemarrow; R-PB, related peripheral blood stem cell; UR-BM, unrelated bonemarrow; CBT, cord blood transplantation; MAC, myeloablative conditioning; RIC,
reduced-intensity conditioning.
Y. Arai et al. / Biol Blood Marrow Transplant 19 (2013) 1683e1689 1685previous studies [7,11,12,14,17,19,20]. Furthermore, the Pico-
Green assay proved to be a powerful time- and labor-saving
tool for evaluating serumNETs in a clinical setting. NET levels
in serum samples were not signiﬁcantly different from those
in plasma samples (data not shown).
Serum NET Levels Increase after Allo-SCT, Especially in
TA-TMA Patients
We compared serumNET levels for all allo-SCT patients at
PRE, Day0, and 4WK. The serum NET levels in subjects before
the conditioning regimen (102.7  4.9 ng/mL [mean 
standard error mean]) and in healthy control subjects (N ¼
10, 107.0  5.2 ng/mL) were similar in both the groups (P ¼
.77). NET levels between Day0 and before transplantation
(PRE) were signiﬁcant in the TMA group (108.1 16.3 ng/mL
versus 91.3  11.7 ng/mL, P ¼ .02) but not signiﬁcant in the
non-TMA group (101.8  4.51 ng/mL versus 104.3  5.36 ng/
mL, P ¼ .52). In contrast, the 4WK levels were signiﬁcantly
elevated compared with the levels before conditioning
regimen in both groups (150.3  13.3 ng/mL, P < .01, in theFigure 1. Survival of patients after allo-SCT. (A) Overall survival was calculated using t
the log-rank test. The 1-year overall survival was signiﬁcantly lower (31.2% versus
signiﬁcantly higher (39.0% versus 9.3% [P ¼ .03]) in the TMA group.TMA group; 119.4  6.2 ng/mL, P ¼ .02, in the non-TMA
group) (Figure 2A). Furthermore, the 4WK levels in the
TMA group were signiﬁcantly higher than those in the non-
TMA group (P¼ .04) (Figure 2A). Next, we calculated the ratio
of serum NET levels at Day0 and 4WK to those before
transplant. The ratio of 4WK-to-PRE levels was signiﬁcantly
higher in the TMA group than in the non-TMA group (1.76 
.13 versus 1.23  .06 [P < .001]) (Figure 2B). Interestingly, the
ratio of Day0-to-PRE levels was also signiﬁcantly higher in
the TMA group (1.18  .05 versus 1.03  .02 [P ¼ .03])
(Figure 2B).
We next examined serum levels of soluble thrombomo-
dulin, a marker for endothelial injury, because TA-TMA is
closely associated with vascular endothelial injury. The 4WK
levels of thrombomodulin were signiﬁcantly elevated
compared with PRE levels in both the TMA and non-TMA
group (Figure 2C). However, there were no differences in
absolute thrombomodulin levels at 4WK (Figure 2C), Day0/
PRE ratio, or 4WK/PRE ratio (Figure 2D) between the TMA
and non-TMA groups, in sharp contrast to the NET levels.he Kaplan-Meier method, and TMA and non-TMA groups were compared using
69.8% [P < .01]) in the TMA group. (B) Nonrelapse mortality at 1- year was
Figure 2. Serum NET trends after allo-SCT. (A) The serum NET levels before conditioning regimen (PRE), on the day of SCT (Day0), and 4 weeks after SCT (4WK) in the
TMA (N ¼ 11) and non-TMA (N ¼ 79) groups. (B) The ratio of serum NET levels at Day0 and 4WK to PRE (Day0/PRE and 4WK/PRE) in the TMA (N ¼ 11) and non-TMA
(N ¼ 79) groups. In the TMA group, Day0/PRE and 4WK/PRE are signiﬁcantly higher than in the non-TMA group. (C) The serum thrombomodulin levels before
conditioning regimen (PRE), on the day of SCT (Day0), and 4 weeks after SCT (4WK) in the TMA (N ¼ 11) and non-TMA (N ¼ 34) groups. (D) The ratio of serum
thrombomodulin levels at Day0 and 4WK to PRE (Day0/PRE and 4WK/PRE) in the TMA (N ¼ 11) and non-TMA (N ¼ 34) groups. *P < .05; **P < .01; ***P < .001.
Y. Arai et al. / Biol Blood Marrow Transplant 19 (2013) 1683e16891686These results suggest that serum NET levels may be more
useful as a predictive marker for TA-TMA.
NET Level Elevation Is a Signiﬁcant Risk Factor for
TA-TMA
To evaluate the potential of NETs as a predictivemarker for
TA-TMA, we created receiver operating characteristic curves
of Day0/PRE and 4WK/PRE ratios (data not shown). Cut-off
values (1.1 and 1.5 for Day0/PRE and 4WK/PRE, respectively)
were deﬁned to maximize the combination of sensitivity and
speciﬁcity, and that of absolute NET levels at 4WK was
determined just above themaximumvalue of healthy control
subjects (140ng/mL). Univariate analysis found a signiﬁcantly
higher incidence of TA-TMA in patients with either Day0/PRE
>1.1 (36 cases) or 4WK/PRE >1.5 (19 cases) than in patients
with either Day0/PRE 1.1 (54 cases; 22.2% versus 5.6%,
P ¼ .01) or 4WK/PRE 1.5 (69 cases; 31.6% versus 4.3%,P < .01), respectively (Figure 3A,B). Furthermore, it was
noteworthy that TA-TMA was more common in patients
whose absolute NET levels were >140 ng/mL 4 weeks after
transplant (24 cases), comparedwith thosewith140 ng/mL
at the same time point (64 cases; 25.0% versus 4.7%, P < .01;
Figure 3C). In the 4WK analysis, 2 patients who developed
TA-TMA before 4 weeks after transplant were excluded.
In contrast, the incidence of TA-TMA was not related to
absolute NET levels at Day0 (data not shown). Day0/PRE
ratio, 4WK/PRE ratio, or absolute NET levels at 4WKwere not
associated with other allo-SCTerelated complications, such
as acute GVHD or bacterial infections (up to Day 100) (data
not shown).
Other signiﬁcant risk factors for TA-TMA were high-risk
SCT (18.8% versus 4.7%, P ¼ .04), and progressive disease
(22.2% versus 5.6%, P ¼ .01; Table 3). Nonsigniﬁcant risk
factors included sex, older age, underlying disease, previous
Figure 3. High NET levels are a risk factor for TA-TMA. (A) The incidence of TA-TMA relative to the Day0/PRE serum NET ratios. (B) The incidence of TA-TMA relative to
the 4WK/PRE serum NET ratios. (C) The incidence of TA-TMA relative to absolute serum NET levels at 4WK. Note that elevations of either the serum NET ratios (Day0/
PRE and 4WK/PRE) or absolute NET levels at 4WK are signiﬁcant risk factors for TA-TMA.
Y. Arai et al. / Biol Blood Marrow Transplant 19 (2013) 1683e1689 1687allo-SCT history, donor source, blood type mismatch, condi-
tioning regimens, type of GVHD prophylaxis, and serum
thrombomodulin levels before SCT or at 4 weeks. Multivar-
iate analysis showed that 4WK NET levels >140 ng/mL
(hazard ratio 4.46; 95% conﬁdence interval, 1.32 to 15.0; P ¼
.01) and Day0/PRE ratios >1.1 (hazard ratio 3.55; 95% conﬁ-
dence interval, 1.03 to 12.2; P ¼ .04) were signiﬁcant, indi-
cating their potential utility as biomarkers for TA-TMA
(Table 3).
Identiﬁcation of NET Deposition in the Glomeruli of TA-
TMA Patients by Immunostaining
Kidney specimens were obtained at autopsy from
patients with TA-TMA (n ¼ 2, Cases 1 and 2). Fragmented
erythrocytes, thrombosis, and ﬁbrins were visible in the
glomerulus after staining with either H & E (Figure 4A),
phosphotungstic acid hematoxylin (Figure 4B), or periodic
acid-Schiff (Figure 4C). After immunoﬂuorescence staining
with MPO and dsDNA, clumps of NETs were visualized
intravenously as weblike, granular structures (Figure 4F,G),
indicating the involvement of NET deposition in the devel-
opment of TA-TMA.
DISCUSSION
Our study results demonstrated that serum NET levels
were elevated 4 weeks after SCT, compared with theTable 3
Risk Factors for TA-TMA
Variables Univariat
Cumulati
at 1 Year
Sex, male/female 16.0/7.5
Age, over/under 50 y 12.5/12.0
Disease, AML/MDS/ALL/ML 17.6/10.0
SCT risk, high/standard 18.8/4.7
Disease status, progressive/controlled 22.2/5.6
Prior allo-SCT, yes/no 20.0/11.2
Donor source, R-BM/R-PB/UR-BM/CBT 5.9/.0/14
ABO mismatch, yes/no 8.0/17.5
Conditioning, MAC/RIC 17.9/7.8
GVHD prophylaxis, CyA/FK506 based 6.2/13.5
4WK-NET value, over/under 140 ng/mL 28.0/6.2
NETs Day0/PRE ratio, over/under 1.1 22.2/5.6
4WK-thrombomodulin level, over/under mean (6.0 ng/mL) 35.3/17.9
PRE-thrombomodulin level, over/under mean (4.0 ng/mL) 23.5/25.0
AML indicates acute myelogenous leukemia; MDS, myelodysplastic syndrome; AL
bonemarrow; R-PB, related peripheral blood stem cell; UR-BM, unrelated bonemar
reduced-intensity conditioning; CyA, cyclosporine A.
* Statistically signiﬁcant.pretransplantation level, and this increase was especially
marked in patients who developed TA-TMA. Furthermore,
the ratio of either Day0/PRE or 4WK/PRE NET levels was
signiﬁcantly higher in the TMA group. NET deposition visu-
alized directly in the renal glomeruli in TA-TMA patients.
At present, it is not clear whether NET formation is
a cause or a consequence of TA-TMA. To solve this issue,
therapeutic intervention to prevent NET formation in
a prospective study is necessary. However, taking all data
into consideration, we speculate that NET formation may be
relevant to the pathogenesis of TA-TMA. Vascular endothelial
cell injury may occur initially because of a variety of allo-
SCTerelated procedures, such as chemotherapy, total body
irradiation, calcineurin inhibitor, and antimicrobial agents
[21]. Subsequently, injured endothelium induces NET
formation, and vice versa [22], resulting in a positive-
feedback cycle between NET formation and endothelial
injury. Indeed, NET formation occurs in proportion to the
severity of endothelial damage after allo-SCT. Binding of
NETs to the endothelium, especially via histones, elastase,
and MPO components, is responsible for NET-mediated
cytotoxicity [20,23]. NETs promote thrombus formation
through interactions with platelets and erythrocytes [24]. In
addition, vascular endothelial cell damage directly activates
the coagulation cascade, leading to intravascular thrombosis
[4]. Finally, NETs cooperate with injured endothelium toe Analysis Multivariate Analysis
ve Incidence
(%)
P Hazard Ratio P
.23
.89
/6.2/14.3 .81
.04* 1.62 (.18-13.9) .66
.01* 2.75 (.42-17.8) .29
.41
.0/14.8 .73
.17
.19
.42
<.01* 4.46 (1.32-15.0) .01*
.01* 3.55 (1.03-12.2) .04*
.19
.86
L, acute lymphoblastic leukemia; ML, malignant lymphoma; R-BM, related
row; CBT, cord blood transplantation; MAC, myeloablative conditioning; RIC,
Figure 4. Immunoﬂuorescence staining of glomeruli in patients with TA-TMA. Kidney specimens were obtained at autopsy from patients with TA-TMA. (A) H & E
staining; characteristic features of TA-TMA, such as fragmented erythrocytes (arrows), thrombosis, and ﬁbrins (arrow heads) are visible. (B) Phosphotungstic acid
hematoxylin staining and (C) periodic acid-Schiff staining showing ﬁbrin deposition in glomeruli. (D and E) H & E staining of glomeruli in Cases 1 (D) and 2 (E). (F and
G) Immunoﬂuorescence staining with MPO and dsDNA in Cases 1 (F) and 2 (G). NETs are visible as weblike structures (arrow heads). The photographs in (F) and (G)
are high-power views of the boxed areas in (D) and (E), respectively. Scale bars represent 50 mm (A-E) and 10 mm (F, G).
Y. Arai et al. / Biol Blood Marrow Transplant 19 (2013) 1683e16891688promote thrombosis in small vessels, leading to hemolysis,
thrombocytopenia, poor end-organ perfusion, and, ulti-
mately, TA-TMA.
TA-TMA is one of the most serious complications after
allo-SCT [4]. In our study, the remission rate of TA-TMA was
approximately 55% (6 of 11 patients). Currently, there is no
optimal management strategy for TA-TMA, and existing
treatments, such as plasma exchange or administration of
fresh frozen plasma and recombinant thrombomodulin, are
only partially effective [21]. Early diagnosis and successful
therapeutic interventions depend on a wealth of knowledge
of the pathophysiology of TA-TMA and the characterization
of early diagnostic biomarkers; our results show that the
Day0/PRE serum NET ratio may be useful in this respect. We
found a signiﬁcant association between a >10% increase in
serum NETs at Day0 versus PRE and TA-TMA morbidity. The
increased Day0/PRE ratio may be related to endothelial cell
damage after the conditioning regimens, because we did not
ﬁnd a direct correlation between Day0/PRE ratio and early
complications, such as acute GVHD and bacterial infection.
Serum NET levels were signiﬁcantly elevated at 4 weeks
after SCT compared with PRE in the TMA as well as the non-TMA patients. The elevation at 4 weeks in the non-TMA
group may, at least in part, reﬂect neutrophil activation to
form NETs by microbial infections after allo-SCT [6,25,26].
NET-dependent microbe trapping usually occurs at a focal
infectious site, and the presence of fragmented NETs in sera
is related to the severity of infection [11,12]. It is notable that
the serum NET levels at 4 weeks after SCT in the TMA group
were signiﬁcantly higher than in the non-TMA group. We
further discovered that patients with NET levels of >140 ng/
mL at 4 weeks after SCT, which was the highest value in
healthy individuals, were prone to TA-TMA but were not at
high risk for bacterial infections. Thus, we speculate that
a positive-feedback loop between endothelial injury and
NETs rather than infection may be the primary cause of
elevated NETs in the TMA group. Only 2 of 11 patients in our
study developed TMA earlier than 4 weeks after SCT, sug-
gesting that the absolute NET levels at 4 week after SCT could
also be a noninvasive diagnostic marker for TA-TMA, avoid-
ing the need for invasive procedures such as biopsies of the
gastrointestinal tract or kidney.
In our study, serum thrombomodulin levels in the TA-
TMA group were not signiﬁcantly different from those in
Y. Arai et al. / Biol Blood Marrow Transplant 19 (2013) 1683e1689 1689the non-TMA group. These results indicate that NETs may be
a superior biomarker for TA-TMA. Because our current study
has some limitations, such as small number and heteroge-
neous group of patients analyzed, a prospective study in
larger populations is necessary to validate the usefulness of
serum NET levels as a predictive marker for TA-TMA. Finally,
disruption of circulating dsDNAs from NETs could be
a potential target for treatment of TA-TMA, as suggested from
animal studies of deep venous thrombosis that showDNase1
or heparin treatment suppresses thrombosis through
reduced NET formation [24,27].
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